State Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM)

State Street Corp decreased its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 7.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,187,466 shares of the company’s stock after selling 176,768 shares during the quarter. State Street Corp owned approximately 3.64% of Immunome worth $31,981,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IMNM. Quest Partners LLC purchased a new position in shares of Immunome in the second quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Immunome in the 2nd quarter worth $97,000. Arizona State Retirement System boosted its holdings in shares of Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Immunome during the third quarter valued at about $219,000. Institutional investors own 44.58% of the company’s stock.

Insiders Place Their Bets

In other news, insider Robert Lechleider bought 15,805 shares of the stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now owns 15,805 shares of the company’s stock, valued at $149,831.40. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CTO Philip Tsai purchased 21,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the acquisition, the chief technology officer now directly owns 21,000 shares in the company, valued at $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought 102,862 shares of company stock valued at $978,045 over the last three months. 8.60% of the stock is owned by company insiders.

Immunome Stock Performance

NASDAQ IMNM opened at $10.97 on Friday. The business’s 50 day moving average price is $12.14 and its 200-day moving average price is $13.35. Immunome, Inc. has a fifty-two week low of $8.15 and a fifty-two week high of $30.96. The company has a market cap of $684.71 million, a P/E ratio of -1.35 and a beta of 1.83.

Analyst Ratings Changes

A number of brokerages recently commented on IMNM. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Piper Sandler lowered their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has an average rating of “Buy” and an average target price of $28.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.